Electronic Patient-Reported Outcomes (ePRO) Analytics With AI Market Report 2026

The electronic patient-reported outcomes (epro) analytics with artificial intelligence (AI) market size has grown rapidly in recent years. It will grow from $1.83 billion in 2025 to $2.11 billion in 2026 at a compound annual growth rate (CAGR) of 15.6%. The growth in the historic period can be attributed to expansion of electronic data capture in clinical trials, growth of digital health adoption, increasing focus on patient-centric research, early adoption of ePRO platforms, rising demand for real-world evidence.

The electronic patient-reported outcomes (epro) analytics with artificial intelligence (AI) market size is expected to see rapid growth in the next few years. It will grow to $3.74 billion in 2030 at a compound annual growth rate (CAGR) of 15.4%. The growth in the forecast period can be attributed to increasing integration of ai in clinical research analytics, rising demand for continuous patient monitoring, expansion of decentralized clinical trials, growing adoption of cloud-based analytics platforms, increasing focus on proactive care interventions. Major trends in the forecast period include increasing adoption of AI-driven symptom pattern recognition, growing use of predictive analytics in patient monitoring, expansion of remote patient engagement platforms, rising integration with clinical trial management systems, enhanced focus on personalized outcome insights.

The growing acceptance of telemedicine and remote patient monitoring is expected to drive growth in the electronic patient-reported outcomes (ePRO) analytics with artificial intelligence (AI) market going forward. Telemedicine involves delivering healthcare services through digital communication technologies, while remote patient monitoring refers to the continuous collection and analysis of patient health data using connected devices and sensors. The increasing use of telemedicine and remote monitoring is fueled by the demand for convenient, accessible, and timely care. Greater reliance on digital health platforms has accelerated the adoption of advanced tools that enable real-time patient data capture and automated insight generation in clinical research. This trend supports the expansion of the ePRO analytics with AI market by enabling continuous, high-quality data collection and intelligent analysis capabilities. For instance, in December 2023, the UK’s National Health Service reported that monthly digital interactions grew significantly, with 33.6 million app users and a 54% increase in monthly logins compared to the previous year, reflecting broader acceptance of digital healthcare engagement. Therefore, the growing use of telemedicine and remote patient monitoring is driving the ePRO analytics with AI market.

Companies in the ePRO analytics with AI market are focusing on innovations such as AI-enabled reporting to enhance data accuracy, accelerate clinical insights, and streamline decision-making in clinical trials. AI-enabled reporting uses artificial intelligence to automatically analyze, interpret, and visualize complex datasets, providing faster and more precise insights for decision-making. For example, in January 2025, Medrio, a US-based provider of clinical-trial technology including electronic case report forms/electronic data capture (CRF/EDC), electronic clinical outcome assessment (eCOA)/ePRO, eConsent, and randomization and trial supply management (RTSM), launched AI-enabled reporting within its clinical data management system/electronic data capture (CDMS/EDC) platform. This feature simplifies data exploration for study teams managing large volumes of clinical trial data and reduces the need for separate reporting tools. Its development involved an early adopter program with sponsors and CROs to ensure relevance to real-world trial workflows.

In May 2024, Eli Lilly and Company, a US-based global pharmaceutical company, acquired Aparito Limited for an undisclosed amount. This acquisition strengthens Eli Lilly’s capabilities in digital health, decentralized clinical trials, and patient-centric data collection by integrating Aparito’s advanced ePRO and AI-driven analytics technologies into its R&D processes. It supports clinical trial efficiency and patient engagement through real-time digital monitoring and data-driven insights. Aparito Limited is a UK-based provider of ePRO and digital health solutions that leverage artificial intelligence, machine learning, and wearable technology to remotely capture and analyze patient data via its Atom5 platform.

Major companies operating in the electronic patient-reported outcomes (epro) analytics with artificial intelligence (AI) market are Oracle Health Sciences, IQVIA Inc., Parexel International Corporation, Veeva Systems Inc., Elekta AB, Kaiku Health, Clario Inc., Medidata Solutions Inc., Signant Health, eClinical Solutions LLC, Medable Inc., YPrime LLC, Kayentis SAS, uMotif Limited, Clinical Ink Inc., Curebase Inc., AiCure LLC, Climedo Health GmbH, Datacubed Health Inc., OpenClinica LLC, Castor EDC BV.

North America was the largest region in the electronic patient-reported outcomes (ePRO) analytics with artificial intelligence (AI) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the electronic patient-reported outcomes (epro) analytics with artificial intelligence (AI) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the electronic patient-reported outcomes (epro) analytics with artificial intelligence (AI) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the ePRO analytics with artificial intelligence market by increasing costs of imported servers, wearable devices, patient monitoring sensors, networking equipment, and advanced computing hardware used in data collection and analytics. Pharmaceutical companies and research organizations in North America and Europe are most affected due to reliance on imported digital health infrastructure, while Asia-Pacific faces cost pressures on device-enabled deployments. These tariffs are increasing implementation costs and extending deployment timelines. However, they are also encouraging cloud-based architectures, regional data processing capabilities, and software-driven innovation that reduce dependency on imported hardware.

The electronic patient-reported outcomes (epro) analytics with artificial intelligence (AI) market research report is one of a series of new reports that provides electronic patient-reported outcomes (epro) analytics with artificial intelligence (AI) market statistics, including electronic patient-reported outcomes (epro) analytics with artificial intelligence (AI) industry global market size, regional shares, competitors with a electronic patient-reported outcomes (epro) analytics with artificial intelligence (AI) market share, detailed electronic patient-reported outcomes (epro) analytics with artificial intelligence (AI) market segments, market trends and opportunities, and any further data you may need to thrive in the electronic patient-reported outcomes (epro) analytics with artificial intelligence (AI) industry. This electronic patient-reported outcomes (epro) analytics with artificial intelligence (AI) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Electronic patient-reported outcomes (ePRO) analytics with artificial intelligence (AI) involves the use of AI technologies to gather, process, and interpret digitally captured patient-reported data, including symptoms, treatment experiences, quality of life, and medication adherence. AI enhances ePRO systems by detecting patterns, predicting health risks, personalizing interventions, and generating actionable insights for clinicians, researchers, and care teams. This approach improves data accuracy, enables early identification of issues, supports clinical decision-making, and increases patient engagement in healthcare and clinical trials.

The main components of ePRO analytics with AI are software, hardware, and services. The software component includes digital platforms that collect patient-reported information and leverage AI algorithms to analyze and interpret data on symptoms, side effects, treatment responses, and quality-of-life measures. These solutions are deployed via on-premises and cloud-based models, providing flexible data management. Applications include clinical trials, patient monitoring, and other healthcare processes, serving end users such as pharmaceutical companies, contract research organizations (CROs), hospitals and clinics, academic and research institutes, and other healthcare organizations.

The electronic patient-reported outcomes (ePRO) analytics with artificial intelligence (AI) market consists of revenues earned by entities by providing services such as artificial intelligence (AI)-enabled electronic patient-reported outcomes (ePRO) platform integration, data analytics and visualization, patient engagement and support, regulatory compliance consulting, system maintenance, and technical support. The market value includes the value of related goods sold by the service provider or included within the service offering. The electronic patient-reported outcomes (ePRO) analytics with artificial intelligence (AI) market also includes sales of artificial intelligence (AI)-powered electronic patient-reported outcomes (ePRO) software platform, mobile electronic patient-reported outcomes (ePRO) data collection app, cloud-based electronic patient-reported outcomes (ePRO) analytics dashboard, wearable-integrated patient monitoring tool, and artificial intelligence (AI)-driven clinical trial reporting system. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.